


**UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes**

Meeting Date: June 6, 2024  
 Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
<b>Meeting called to order</b>	G. Shutzberg		5:01PM EST	
<b>A. Minutes from previous meetings</b>	G. Shutzberg	<b>Review of Minutes from March 7, 2024</b>	Minutes reviewed, approved	Yes
<b>B. Formulary Review - New Drugs</b>	M. Reisman	<b>lwiifin</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	M. Reisman	<b>Rezdifra</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Comment: Dr. Pappalardo asked are patients able to easily access a trial in their local areas? Maddie stated that trails for Rezdifra are on-going, however Rezdifra is currently FDA approved & is available for all patients, they do not need to be registered in a clinical trial to get this medication.		
	M. Reisman	<b>Rivfloza</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	M. Reisman	<b>Truqap</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	S. Kramzer	<b>Agamree</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	S. Kramzer	<b>Augtyro</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	S. Kramzer	<b>Cabtreo</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	S. Kramzer	<b>Eohilla</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	M. Reisman	<b>Vevye</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		<b>Cyclosporine</b>		
		Recommendation: • Preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		<b>Xiidra</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	M. Reisman	<b>Wainua</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	M. Reisman	<b>Xphozah</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	M. Reisman	<b>Zilbrysq</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	S. Kramzer	<b>Fabhalta</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	S. Kramzer	<b>Ogsiveo</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
	S. Kramzer	<b>Zepbound</b>		
		Recommendation: • Benefit Exclusion (Non-preferred with prior authorization where weight loss coverage required)	Motion made, seconded, and carried to accept recommendation	11:0
		Comment: Dr. Pappalardo asked what happens when Zepbound is stopped and are their any lasting effects with this medication? Steve answered it is very similar to the other GLP-1s, where the weight does return, so there is no advantage verses any of the other agents in the drug class. Dr. Williams asked are we approving any GLP-1s for weight loss? Steve replied, currently Rhode Island is the only UHC defined market that would approve a GLP-1 medication for weight loss. Dr. Williams said that is somewhat short-sighted as many of these patients have metabolic comorbidities along with obesity. Steve stated that currently in the Medicaid space most of our Medicaid partners designate weight loss medications as a benefit exclusion. It is only in the markets where the Medicaid state partner has provided direction to cover weight loss medications that they are not a benefit exclusion.		
	S. Kramzer	<b>Zoryve</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0

<b>C. Formulary Review - New Formulations</b>	M. Reisman	<b>Confirm Review of New Formulations Grid</b>	Yes/No	Yes
		Recommendation: • <b>Zymfentra</b> : Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
<b>D. Formulary Review - PDL Modifications</b>	M. Reisman	<b>Confirm Review of PDL Modifications Grid</b>	Yes/No	Yes
		Recommendation: • <b>Kezara</b> : Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Tyenne prefilled syringe and autoinjector</b> : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Revimid</b> : Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Farxiga</b> : Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Wegovy</b> : Remain benefit exclusion across all applicable lines of business (non-preferred with prior authorization in lines of business that require coverage)	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Sunlenca</b> : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Vancomycin 150mg, 250mg capsule</b> : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Vancomycin 25mg/mL solution</b> : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Vancomycin 50mg/mL solution</b> : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Firvanq 25mg/mL, 50mg/mL solution</b> : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Nutropin</b> : Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Omnitrope</b> : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Mometasone furoate nasal spray</b> : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		Recommendation: • <b>Ondansetron 4mg/5mL oral solution</b> : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
<b>E. Formulary Review - New Drugs- Medical</b>	M. Reisman	<b>Confirm Review of New Drugs- Medical Grid</b>	Yes/No	Yes
		<b>Casgevy</b> Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		<b>Lyfgenia</b> Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		<b>Loqtorzi</b> Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
		<b>Adzynma</b> Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	11:0
<b>F. Formulary Review - Drugs Evaluated Per Grid</b>	S. Kramzer	<b>Apply recommendations as outlined in grid</b>	Motion made, seconded, and carried to accept recommendation	11:0
<b>G. Clinical Guidelines</b>	S. Kramzer	<b>Clinical Guideline Review</b>		
		<b>Apply New Pharmacy Guidelines</b>	Motion made, seconded, and carried to accept recommendation	11:0
		<b>Continue to Apply Pharmacy Guidelines Requiring Modifications</b>	Motion made, seconded, and carried to accept recommendation	11:0
		<b>Remove Pharmacy Guidelines Requiring Archival</b>	Motion made, seconded, and carried to accept recommendation	11:0
<b>H. Quality Monitoring</b>	L. Smith/ M. Reisman	<b>Confirm Review of Quality Data</b>	Yes/No	Yes
	L. Smith	DUR Review		
	M. Reisman	Drug Recalls – 1st Quarter 2024		
	M. Reisman	Top 25 Drugs by Spend and Volume – 1st Quarter 2024		
	M. Reisman	Top 10 Drugs Requested - Approvals and Denials – 1st Quarter 2024		
	M. Reisman	Grievances and Appeals Data – 1st Quarter 2024		
	M. Reisman	Inter-Rater Reliability (IRR) – 1st Quarter 2024 • Pharmacists		
<b>Adjournment</b>	G. Shutzberg		6:48PM EST	
Respectfully Submitted to the Committee,				
 James P. Hancovsky, M.S.I.A., R.Ph. Chief Pharmacy Officer, UHC C&S				